3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase 1
7
Phase 1/2
4
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
196
Other solid neoplasm
6
Tumor-Agnostic
5
Gynecologic
5
Head & Neck
2
Gastrointestinal
2
CNS
2
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
65
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
41
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
30
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Triptorelin Pamoate
23
Sunitinib
23
Nivolumab
23
Radiation
22
apalutamide
21
Doxorubicin
20
darolutamide
18
Gonadotropin-Releasing Hormone
18
cabozantinib
16
abiraterone
16
Specimen Handling
16
Radiosurgery
16
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pemetrexed
×
Genitourinary
×
Clear all
NCT03193788
2017-06-21
PREMIER
Asan Medical Center
Phase 3
Unknown
74 enrolled